For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 2,409,575 | 4,758,876* | 5,430,757 | 8,505,229 |
| General and administrative | 1,137,343 | 3,251,534* | 2,570,375 | 1,663,503 |
| Loss from operations | -3,546,918 | -8,010,410* | -8,001,132 | -10,168,732 |
| Interest income | 562,977 | 832,757* | 788,694 | 872,038 |
| Interest expense | 468,678 | 485,528.5* | 475,903 | 470,618 |
| Total other income, net | 94,299 | 347,228.5* | 312,791 | 401,420 |
| Net loss | -3,452,619 | -7,663,181.5 | -7,688,341 | -9,767,312 |
| Basic EPS | -0.06 | -0.128 | -0.13 | -0.16 |
| Diluted EPS | -0.06 | -0.128 | -0.13 | -0.16 |
| Basic Average Shares | 60,319,289 | 59,997,291 | 60,126,850 | 60,045,530 |
| Diluted Average Shares | 60,319,289 | 59,997,291 | 60,126,850 | 60,045,530 |
Aldeyra Therapeutics, Inc. (ALDX)
Aldeyra Therapeutics, Inc. (ALDX)